Abaloparatide (brand name Tymlos) is a human parathyroid hormone related peptide [PTHrP(1-34)]
analog indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Abaloparatide is a PTHrP(1-34) analog which acts as an agonist at the PTH1 receptor (PTH1R).
This results in activation of the cAMP signaling pathway in target cells. In rats and monkeys,
abaloparatide had an anabolic effect on bone, demonstrated by increases in BMD and bone
mineral content (BMC) that correlated with increases in bone strength at vertebral and/or
nonvertebral sites. Abaloparatide was approved in April 28, 2017 by the FDA (as Tymlos) for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Recommended dose is 80 ug subcutaneously once daily; patients should receive supplemental calcium and vitamin D if dietary intake is inadequate.
Administer as a subcutaneous injection into periumbilical region of abdomen. Administer initially where the patient can sit or lie down in case symptoms of orthostatic hypotension occur.
Route of Administration:
Other
Subunit 0
Showing 1 to 2 of 2 entries
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Biological Half-life | PHARMACOKINETIC |
1.7 hours (average) |
|
|||
| Molecular Formula | CHEMICAL |
ESTIMATED
C174H304N56O51 |
||||
| MOL_WEIGHT:SEQUENCE(CALCULATED) | CHEMICAL |
SEQUENCE
3960 DA (average) |
||||
| Volume of Distribution | PHARMACOKINETIC |
50 LITERS (average) |
|
|||